Transthyretin Silencer Shows Benefits in Madrid Amyloidosis Study

A Madrid study, published in *Nature Medicine*, reports that a transthyretin silencer significantly improved outcomes for patients with transthyretin amyloidosis. The research, presented at the European Congress of Cardiology, offers a new approach to managing the organ damage caused by this protein buildup. It’s a big deal for folks whose bodies struggle with protein misfolding.